EGFR tyrosine kinase inhibitors
GPTKB entity
Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:category |
targeted therapy
antineoplastic agent |
| gptkbp:discoveredIn |
early 2000s
|
| gptkbp:example |
gptkb:afatinib
gptkb:erlotinib gptkb:gefitinib gptkb:osimertinib gptkb:dacomitinib |
| https://www.w3.org/2000/01/rdf-schema#label |
EGFR tyrosine kinase inhibitors
|
| gptkbp:mechanismOfAction |
inhibit EGFR tyrosine kinase activity
|
| gptkbp:resistantTo |
gptkb:T790M_mutation
C797S mutation |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
rash interstitial lung disease |
| gptkbp:target |
gptkb:epidermal_growth_factor_receptor
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
other EGFR-mutant cancers |
| gptkbp:bfsParent |
gptkb:L858R
gptkb:T790M |
| gptkbp:bfsLayer |
6
|